Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Pierre Cordelier

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2096-7967; OpenAlex author ID A5081053692. Sources: OpenAlex.

Their work

Papers
36 (first author 1, last author 19)
Trials
0
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 5 papers · 2014: none · 2015: 4 papers · 2016: 4 papers · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 5 papers · 2025: 1 paper · 2026: 3 papers

Papers 36

  1. [Oncolytic viruses and pancreatic cancer: rethinking the approach to overcome therapeutic resistance]. Last author DOI 10.1051/medsci/2026115↗
  2. SG33, a Vaccine Strain of Myxoma Virus with Oncolytic Potential, Exploits Macropinocytosis and Clathrin-Mediated Endocytosis for Entry into Pancreatic Cancer C… Last author DOI 10.1177/10430342261441043↗
  3. A genome-wide CRISPR-Cas9 screen identifies TGN46 as a host determinant for H-1PV susceptibility in pancreatic adenocarcinoma Last author DOI 10.64898/2026.03.06.710102↗
  4. [Oncolytic viruses for the management of pancreatic cancer: ongoing trials and therapeutic perspectives]. Last author DOI 10.1684/vir.2025.1100↗
  5. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  6. Minute virus of mice shows oncolytic activity against pancreatic cancer cells exhibiting a mesenchymal phenotype. Last author DOI 10.1016/j.omton.2024.200780↗
  7. Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients. Last author DOI 10.1038/s41598-024-76903-y↗
  8. Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells. Last author DOI 10.1038/s42003-024-06760-y↗
  9. Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs. Last author DOI 10.1158/0008-5472.can-22-3219↗
  10. Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer. Last author DOI 10.1016/j.omtm.2023.03.005↗
  11. Pancreatic Cancer Cell and Gene Biotherapies: Past, Present, and Future. Last author DOI 10.1089/hum.2022.210↗
  12. Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach. Co-author DOI 10.3390/cancers15030761↗
  13. Cytidine deaminase regulates mitochondrial biogenesis in pancreatic cancer cells Last author DOI 10.1101/2022.12.15.520429↗
  14. Upregulated Apelin Signaling in Pancreatic Cancer Activates Oncogenic Signaling Pathways to Promote Tumor Development. Co-author DOI 10.3390/ijms231810600↗
  15. Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component. Co-author DOI 10.15252/emmm.202013502↗
  16. One Two Punch: Combination Chemotherapy Knocks Out Pancreatic Cancer. First author DOI 10.1016/j.ymthe.2020.07.014↗
  17. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Last author DOI 10.1038/s41575-019-0245-4↗
  18. Expression and Role of MicroRNAs from the miR-200 Family in the Tumor Formation and Metastatic Propensity of Pancreatic Cancer. Co-author DOI 10.1016/j.omtn.2019.06.015↗
  19. Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers11060852↗
  20. Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. Co-author DOI 10.3390/ijms18061231↗
  21. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. Co-author DOI 10.1016/j.ejca.2015.11.012↗
  22. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1038/ctg.2016.18↗
  23. The Promise of Gene Therapy for Pancreatic Cancer. Last author DOI 10.1089/hum.2015.141↗
  24. Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Last author DOI 10.1089/hum.2015.151↗
  25. First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings. Last author DOI 10.1038/mt.2015.1↗
  26. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic… Co-author DOI 10.1097/mcg.0000000000000053↗
  27. IL17 Functions through the Novel REG3β-JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-15-0896↗
  28. Salivary MicroRNA in Pancreatic Cancer Patients. Last author DOI 10.1371/journal.pone.0130996↗
  29. miRNA in clinical practice: pancreatic cancer. Last author DOI 10.1016/j.clinbiochem.2013.03.019↗
  30. Targeting miR-21 for the therapy of pancreatic cancer. Last author DOI 10.1038/mt.2013.35↗
  31. [Kras oncogene and pancreatic cancer: thirty years after]. Co-author DOI 10.1051/medsci/20132911015↗
  32. KRAS Mutations and Their Correlation With Survival of Patients With Advanced Pancreatic Cancer Co-author DOI 10.1097/mpa.0b013e31826b388b↗
  33. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. Co-author DOI 10.1371/journal.pone.0055513↗
  34. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. Co-author DOI 10.1016/j.pan.2011.12.003↗
  35. Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination … Co-author DOI 10.1186/1471-2407-12-15↗
  36. Molecular endoscopic ultrasound for diagnosis of pancreatic cancer. Last author DOI 10.3390/cancers3010872↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Louis Buscail · 27 shared papers, 2011–2026 · strength 3.60
  2. Naïma Hanoun · 10 shared papers, 2013–2026 · strength 1.34
  3. Nelson Dusetti · 6 shared papers, 2022–2026 · strength 1.30
  4. Barbara Bournet · 14 shared papers, 2011–2024 · strength 1.19
  5. Stéphane Bertagnoli · 3 shared papers, 2025–2026 · strength 1.02
  6. Jérôme Torrisani · 9 shared papers, 2011–2024 · strength 0.72
  7. Audrey Lumeau · 4 shared papers, 2020–2024 · strength 0.70
  8. Guillaume Labrousse · 3 shared papers, 2024–2026 · strength 0.70
  9. Nikolaos Kontopoulos · 2 shared papers, 2025–2026 · strength 0.67
  10. Marion Gayral · 6 shared papers, 2013–2024 · strength 0.62
  11. Fabrice Muscari · 7 shared papers, 2012–2024 · strength 0.58
  12. Audrey Francès · 4 shared papers, 2022–2024 · strength 0.58
  13. Charlotte Maulat · 3 shared papers, 2019–2024 · strength 0.50
  14. Agathe Redouté · 1 shared paper, 2025 · strength 0.37
  15. Étienne Buscail · 2 shared papers, 2019–2023 · strength 0.32
  16. Lorraine Quillien · 1 shared paper, 2023 · strength 0.31
  17. Margaux Vienne · 1 shared paper, 2024 · strength 0.23
  18. Guillaume Le Cosquer · 1 shared paper, 2023 · strength 0.22
  19. Odile Barbey · 2 shared papers, 2015–2023 · strength 0.21
  20. Julie Guillermet‐Guibert · 2 shared papers, 2021–2022 · strength 0.21
  21. Cindy Canivet · 1 shared paper, 2024 · strength 0.18
  22. Flavie Sicard · 4 shared papers, 2012–2015 · strength 0.17
  23. Abdessamad El Kaoutari · 1 shared paper, 2024 · strength 0.15
  24. Carline Chaves-Almagro · 1 shared paper, 2022 · strength 0.12
  25. Bernard Masri · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.